Sonire Therapeutics Closes $18 Million Series A Financing to Advance Breakthrough HIFU Therapy for Pancreatic Cancer, Expands U.S. Clinical Development

Led by Santé, the funding will support completion of the world's first randomized HIFU trial for pancreatic cancer, and accelerate U.S. clinical programs for the company's anesthesia-free, outpatient sonic therapy PALO ALTO, Calif., April 15, 2026 /PRNewswire/ -- Sonire Therapeutics, a...